WO2001029178A3 - Gene 1 de reponse primaire a l'erythropoietine (epo), gene eprg1 - Google Patents

Gene 1 de reponse primaire a l'erythropoietine (epo), gene eprg1 Download PDF

Info

Publication number
WO2001029178A3
WO2001029178A3 PCT/US2000/029072 US0029072W WO0129178A3 WO 2001029178 A3 WO2001029178 A3 WO 2001029178A3 US 0029072 W US0029072 W US 0029072W WO 0129178 A3 WO0129178 A3 WO 0129178A3
Authority
WO
WIPO (PCT)
Prior art keywords
eprg1
primary response
response gene
epo
epo primary
Prior art date
Application number
PCT/US2000/029072
Other languages
English (en)
Other versions
WO2001029178A2 (fr
Inventor
Susan B Dillon
Kenneth A Lord
Andrew G King
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Priority to JP2001532164A priority Critical patent/JP2003520577A/ja
Priority to EP00975323A priority patent/EP1224220A2/fr
Publication of WO2001029178A2 publication Critical patent/WO2001029178A2/fr
Publication of WO2001029178A3 publication Critical patent/WO2001029178A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

Cette invention, qui a trait à des polypeptides ainsi qu'à des polynucléotides EPRG1, concerne également des procédés permettant de produire ces polypeptides par des techniques de recombinaison. L'invention porte, de plus, sur des méthodes d'utilisation des polypeptides et des polynucléotides EPRG1 en thérapeutique ainsi que sur des méthodes diagnostiques liées à ceux-ci.
PCT/US2000/029072 1999-10-21 2000-10-19 Gene 1 de reponse primaire a l'erythropoietine (epo), gene eprg1 WO2001029178A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2001532164A JP2003520577A (ja) 1999-10-21 2000-10-19 Ｅｐｏ一次応答遺伝子１、ｅｐｒｇ１
EP00975323A EP1224220A2 (fr) 1999-10-21 2000-10-19 Gene 1 de reponse primaire a l'erythropoietine (epo), gene eprg1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42215399A 1999-10-21 1999-10-21
US09/422,153 1999-10-21

Publications (2)

Publication Number Publication Date
WO2001029178A2 WO2001029178A2 (fr) 2001-04-26
WO2001029178A3 true WO2001029178A3 (fr) 2001-09-13

Family

ID=23673614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029072 WO2001029178A2 (fr) 1999-10-21 2000-10-19 Gene 1 de reponse primaire a l'erythropoietine (epo), gene eprg1

Country Status (3)

Country Link
EP (1) EP1224220A2 (fr)
JP (1) JP2003520577A (fr)
WO (1) WO2001029178A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
JPWO2003072778A1 (ja) * 2002-02-27 2005-06-23 株式会社ジェノックス創薬研究所 アレルギー性疾患の検査方法
EP1734982A4 (fr) * 2004-03-04 2009-08-05 Univ Vanderbilt Polypeptides socs pour inhiber la signalisation induite par la cytokine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0877030A2 (fr) * 1997-05-07 1998-11-11 Smithkline Beecham Corporation Gène en réponse primaire à l'EPO 1 (EPRG1)
WO1999003993A2 (fr) * 1997-07-18 1999-01-28 Schering Corporation Suppresseurs de signalement de cytokine et reactifs correspondants
WO1999023220A1 (fr) * 1997-11-03 1999-05-14 Incyte Pharmaceuticals, Inc. Suppresseur de la signalisation cytokinaire

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0877030A2 (fr) * 1997-05-07 1998-11-11 Smithkline Beecham Corporation Gène en réponse primaire à l'EPO 1 (EPRG1)
WO1999003993A2 (fr) * 1997-07-18 1999-01-28 Schering Corporation Suppresseurs de signalement de cytokine et reactifs correspondants
WO1999023220A1 (fr) * 1997-11-03 1999-05-14 Incyte Pharmaceuticals, Inc. Suppresseur de la signalisation cytokinaire

Also Published As

Publication number Publication date
JP2003520577A (ja) 2003-07-08
WO2001029178A2 (fr) 2001-04-26
EP1224220A2 (fr) 2002-07-24

Similar Documents

Publication Publication Date Title
EP1001023A3 (fr) Frizzled-4, un possible récepteur pour Wnt
EP0939124A3 (fr) Séquences de la MBGP1
WO2001066690A3 (fr) Nouveaux composes
WO2001072961A3 (fr) Nouveaux composes
EP0911399A3 (fr) HTHBZ47, un clone apparenté à une kringle
WO1999035266A3 (fr) Urotensine humaine ii
EP0879888A3 (fr) Polypeptides patched-2 et polynucléotides et leurs procédés de fabrication
EP0943684A3 (fr) Polypeptides et polynucléotides ressemblant à frizzled
EP0885959A3 (fr) Protéine Wnt-5b humaine
WO2001029178A3 (fr) Gene 1 de reponse primaire a l'erythropoietine (epo), gene eprg1
EP0887416A3 (fr) Enzyme AFC1 humaine
WO2001004141A3 (fr) Seripancrine
EP0877030A3 (fr) Gène en réponse primaire à l'EPO 1 (EPRG1)
WO2001032864A3 (fr) Nouveaux polypeptides de type gpcr_kd5 et sequences d'adn correspondantes
WO2001083744A3 (fr) Nouvelle proteine echangeuse sodium-calcium
WO2002004600A3 (fr) Nouveaux composes
EP0887415A3 (fr) RCE1 humain
EP0911391A3 (fr) Clone HWHHJ20
EP0890646A3 (fr) HE2NW40 Sérine protéase
WO1999011783A3 (fr) Polypeptides de boite t
EP0882791A3 (fr) WNT-11 Polypeptides
EP0937777A3 (fr) Récepteurs de GABA et leurs utilisations
EP0875570A3 (fr) Polypeptides neurodégénératives HHPDZ65
WO2000070036A3 (fr) Molecules exprimees dans l'hippocampe
WO2001068816A8 (fr) Variant-3 du gene humain de l'histamine h3

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 532164

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000975323

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000975323

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000975323

Country of ref document: EP